SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
NEW YORK, May 12, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) securities between February 29, 2016 and May 4, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
